Myasthenia gravis: vizsgálatok itt: Lengyelország
22 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 11.. Ask the study team whether a trial fits you.
- 2. fázisTaking peopleSafety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients with Myasthenia Gravis
- Where
- Cracow, Katowice, Lodz, Lublin, Warsaw
- Életkor
- 18 év and over
- People
- 59 worldwide
- Run by
- NMD Pharma A/S
See details and how to join2023-507539-40-00 · EU 2023-507539-40-00 - 3. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
- Where
- Cracow, Katowice, Lublin, Poznan, Warsaw, Zabrze
- Életkor
- 18 év and over
- People
- 120 worldwide
- Run by
- UCB Biopharma SRL
See details and how to joinNCT07463521 · EU 2025-524756-54-00 - 3. fázisTaking peopleA Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
- Where
- Cracow, Katowice, Lublin, Poznan, Warsaw, Zabrze
- Életkor
- 18 év and over
- People
- 100 worldwide
- Run by
- UCB Biopharma SRL
See details and how to joinNCT07465289 · EU 2025-524757-14-00 - 3. fázisTaking peopleA Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
- Where
- Bydgoszcz, Cracow, Katowice, Lublin, Warsaw
- Életkor
- 18 év and over
- People
- 199 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT04951622 · EU 2023-504152-97-00 - 2/3. fázisTaking peopleA Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis
- Where
- Katowice, Warsaw
- Életkor
- 12 év to 17 év
- People
- 8 worldwide
- Run by
- UCB Biopharma SRL
See details and how to joinNCT06055959 · EU 2022-502072-23-00 - 2/3. fázisTaking peopleA Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis
- Where
- Gdansk
- Életkor
- 2 év to 17 év
- People
- 12 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT05265273 · EU 2022-502539-21-00 - 2. fázisTaking peopleADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis
- Where
- Bydgoszcz, Cracow, Katowice, Lublin, Poznan, Warsaw
- Életkor
- 18 év and over
- People
- 40 worldwide
- Run by
- argenx
See details and how to joinNCT07673627 · EU 2025-522939-33-00 - 2/3. fázisCsak meghívásosEvaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis
- Where
- Gdansk, Katowice, Warsaw
- Életkor
- 2 év to 18 év
- People
- 12 worldwide
- Run by
- argenx
See details and how to joinNCT05374590 · EU 2023-507379-23-00 - 3. fázisTaking peopleA Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)
- Where
- Bydgoszcz, Cracow, Katowice, Lublin, Poznan, Skorzewo, Warsaw, Wroclaw
- Életkor
- 18 év to 80 év
- People
- 195 worldwide
- Run by
- Dianthus Therapeutics
See details and how to joinNCT07647510 · EU 2026-525298-38-00 - 2. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)
- Where
- Cracow, Katowice, Kielce, Lodz, Lublin, Poznan, Zabrze, Zory
- Életkor
- 18 év and over
- People
- 120 worldwide
- Run by
- TG Therapeutics, Inc.
See details and how to joinNCT07673744 · EU 2025-524630-26-00 - No phaseTaking peopleADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
- Where
- Bydgoszcz, Katowice, Krakow, Warsaw
- Életkor
- 18 év and over
- People
- 70 worldwide
- Run by
- argenx
See details and how to joinNCT07294170 - 2. fázisTaking peopleA Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)
- Where
- Bydgoszcz, Katowice
- Életkor
- 2 év to 17 év
- People
- 15 worldwide
- Run by
- Amgen
See details and how to joinNCT06987539 · EU 2025-520993-20-00 - 3. fázisTaking peopleEfficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
- Where
- Cracow, Gdansk, Warsaw, Zabrze
- Életkor
- 18 év and over
- People
- 264 worldwide
- Run by
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
See details and how to joinNCT06463587 · EU 2023-507746-83-00 - 1/2. fázisTaking peopleA Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Safety and Efficacy of Aritinercept, a Dual BAFF/APRIL Inhibitor, in Patients with Generalized Myasthenia Gravis
- Where
- Bydgoszcz, Cracow, Katowice, Lublin, Poznań, Skorzewo, Warsaw, Zabrze
- Életkor
- 18 év and over
- People
- 38 worldwide
- Run by
- Aurinia Pharmaceuticals Inc.
See details and how to join2025-525127-27-00 · EU 2025-525127-27-00 - 3. fázisCsak meghívásosAn Open-label Extension Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis
- Where
- Katowice, Warsaw
- Életkor
- 12 év to 17 év
- People
- 8 worldwide
- Run by
- UCB Biopharma SRL
See details and how to joinNCT06435312 · EU 2022-502073-42-00 - 2/3. fázisTaking peopleA Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis
- Where
- Gdansk, Katowice, Warsaw
- Életkor
- 2 év to 17 év
- People
- 12 worldwide
- Run by
- argenx
See details and how to joinNCT06392386 · EU 2023-506159-12-00 - 2. fázisTaking peopleADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
- Where
- Bydgoszcz, Cracow, Katowice, Warsaw
- Életkor
- 18 év and over
- People
- 70 worldwide
- Run by
- argenx
See details and how to joinNCT07284420 · EU 2025-522492-28-00 - No phaseTaking peopleRavulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis
- Where
- Bydgoszcz, Gdansk, Katowice, Krakow, L DZ, Lublin, Poznan, Szczecin, Warsaw, Wroclaw
- Életkor
- 18 év and over
- People
- 50
- Run by
- AstraZeneca
See details and how to joinNCT06909253 - 2. fázisTaking peopleSafety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis
- Where
- Katowice, Krakow, Lublin, Myślenice, Warsaw
- Életkor
- 18 év and over
- People
- 84 worldwide
- Run by
- NMD Pharma A/S
See details and how to joinNCT06414954 - 3. fázisTaking peopleStudy to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
- Where
- Cracow, Gdansk, Katowice, Lublin, Warsaw
- Életkor
- 18 év to 80 év
- People
- 231 worldwide
- Run by
- Immunovant Sciences GmbH
See details and how to joinNCT07039916 · EU 2024-515979-35-00 - 3. fázisTaking peoplePK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis
- Where
- Warsaw
- Életkor
- 6 év to 17 év
- People
- 12 worldwide
- Run by
- Alexion Pharmaceuticals, Inc.
See details and how to joinNCT06607627 · EU 2024-515157-17-00 - 1/2. fázisTaking peopleA Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia Gravis
- Where
- Katowice, Nowa Sol, Poznan
- Életkor
- 18 év to 74 év
- People
- 96 worldwide
- Run by
- ImmunAbs Inc.
See details and how to joinNCT07250750 · EU 2025-522406-20-00